Inovio inventory forecast 2025 refers back to the predicted worth of Inovio Prescription drugs’ (INO) inventory in 2025. Inventory forecasts are primarily based on numerous components comparable to the corporate’s monetary efficiency, trade traits, and general financial situations.
Inovio is a clinical-stage biotechnology firm targeted on creating and commercializing DNA-based immunotherapies for infectious ailments and most cancers. The corporate’s lead product candidate, INO-4800, is a DNA vaccine for COVID-19 that’s presently in Section 3 scientific trials. Inovio additionally has a pipeline of different DNA-based vaccines in improvement for numerous infectious ailments and most cancers indications.
